NCT07292714
Recruiting
Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate Efficacy and Safety of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Mabwell (Shanghai) Bioscience Co., Ltd.50 sites in 1 country360 target enrollmentStarted: July 15, 2025Last updated:
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 360
- Locations
- 50
- Primary Endpoint
- The annualized incidence rate of moderate to severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD） within 52 weeks
Overview
Brief Summary
The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety of 9MW1911 in patients with Chronic Obstructive Pulmonary Disease (COPD).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •\- 1.Male or Female patients must be 40 to 75 years of age inclusive； 2.Physician diagnosis of COPD for at least 1 year at screening； 3.Documented history of \>= 2 moderate or \>=1 severe COPD exacerbations within 12 months prior to screening.
- •4.Moderate-to-severe COPD with post-BD FEV1/FVC rato\<0.7 and a post-BD FEV1%predicted ≥20% and\<80% at screening； 5.Body Mass Index (BMI) of 16 kg/m² to 32 kg/m²； 6.Current tobacco smoker or former smoker with a history of smoking ≥ 10 pack-years 7.Participants with standard of care controller therapy, for ≥3 months prior to Screening and at a stable dose of controller therapy for at least 1 month prior to the screening；
Exclusion Criteria
- •1.Current diagnosis of asthma or documented history of asthma; 2.Diagnosis of Alpha-1 Antitrypsin Deficiency； 3.History of other clinically significant pulmonary diseases apart from COPD: such as sarcoidosis,interstitial lung diseases, bronchiectasis,cystic fibrosis，constrictive bronchiolitis,severe pulmonary hypertension or other active pulmonary diseases; 4.Long-term treatment with oxygen (oxygen therapy time \>15h/day) or mechanical ventilation, or clinically significant apnea requiring continuous positive airway pressure (CPAP) or non-invasive positive pressure ventilation (NIPPV); 5.History of lung pneumonectomy, or lung volume reduction within 12 months prior to screening，or planned to undergo lung volume reduction surgery (LVRS) during the study period; 6.Patients in the acute phase of pulmonary rehabilitation(participating in, or scheduled for a pulmonary rehabilitation program within 4 weeks of screening); 7.Uncured upper or lower respiratory tract infections during the screening period; 8.Moderate to severe COPD exacerbations within 4 weeks prior to screening or during the screening period； 9.Any infection requiring hospitalization for ≥24 hours and/or treatment with oral, IV, or IM antibiotics within 4 weeks prior to screening or during the screening period; 10.Received treatment with oral, IV, or intramuscular (IM) corticosteroids (\>10 mg/day prednisone or equivalent dose) within 4 weeks prior to starting study medication; 11.Myocardial infarction, unstable angina within 12 months prior to screening;or heart failure (NYHA Class III or IV) within 6 months prior to screening； 12.History of ventricular arrhythmias or risk factors for ventricular arrhythmias, such as structural heart disease (e.g., severe left ventricular systolic dysfunction, severe left ventricular hypertrophy ), family history of unexplained sudden death or long QT syndrome；
- •experienced transient ischemic attack or stroke within 6 months prior to screening; 14.with unstable cardiovascular diseases, such as pulmonary embolism or deep vein thrombosis that occurred within 6 months before screening, which the researchers believe may put the patient at risk or have a negative impact on the research results; 15.Known active tuberculosis or nontuberculous mycobacterial infection (subjects with positive interferon - γ release assay (IGRA) during the screening period, if evaluated as inactive tuberculosis by the researcher based on clinical manifestations and imaging examinations, etc., can participate in this study); 16.Positive for human immunodeficiency virus antibody (HIV-Ab), or positive for hepatitis B surface antigen (HBsAg) with HBV-DNA copies \> 1000 IU/mL or above the upper limit of normal (ULN) of the study center, or positive for hepatitis C virus antibody (HCV-Ab) with HCV-RNA copies above the ULN of the study center, or positive for Treponema pallidum antibody.
- •17.With active autoimmune disease or receiving immunosuppressive therapy for an autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) are excluded.
- •18\. with any active malignancy or a history of malignancy (except for low-grade tumors deemed cured ≥5 years before screening, such as cervical carcinoma in situ or basal cell carcinoma).
- •19.received a live attenuated vaccine within 4 weeks prior to screening or during the screening period.
- •20.received any biologic therapy (e.g., omalizumab, dupilumab, and/or anti-interleukin-5 therapy) within 3 months prior to screening ; 21.received any investigational therapy within 3 months prior to screening or within 5 drug-elimination half-lives, whichever is longer.
- •22.Any clinically significant ECG abnormality deemed by the investigator to potentially affect study conduct, such as QTc prolongation (QTcF \> 450 ms for males, \> 470 ms for females).
- •23.Alanine aminotransferase (ALT) \>= 2 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) \>= 2 times ULN; Total bilirubin \>= 1.5 times ULN.
- •24.Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m
- •25.with any serious medical condition or clinically significant laboratory abnormality（in investigator's judgment） that could compromise the subject's safety or ability to participate in or complete the study.
Arms & Interventions
Phase II 9MW1911
Experimental
9MW1911 is administered intravenously in two dose levels. Each dose group include 120 patients.
Intervention: 9MW1911 (Drug)
Phase II Placebo
Placebo Comparator
Phase II Placebo is administered intravenously. this group includes 120 patients.
Intervention: Phase II placebo (Drug)
Outcomes
Primary Outcomes
The annualized incidence rate of moderate to severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD） within 52 weeks
Time Frame: Baseline up to week 52
Within a 52-week period, the number of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is converted to an annual incidence rate.
Secondary Outcomes
- Changes from baseline in post-bronchodilator FVC(Weeks 0, 4, 8, 12,24,36,52)
- Changes from baseline in pre-bronchodilator FEV1(Weeks 0, 4, 8, 12,24,36,52)
- Changes from baseline in post-bronchodilator FEV1(Weeks 0, 4, 8, 12,24,36,52)
- Changes from baseline in pre-bronchodilator FVC(Weeks 0, 4, 8, 12,24,36,52)
- Time to first moderate to severe Chronic Obstructive Pulmonary Disease Acute Exacerbation (AECOPD) from baseline to week 52.(Baseline to week 52)
- Annualized rate of moderate to severe AECOPD over the 52-week treatment period.(Baseline to week 52)
- Time to first severe Chronic Obstructive Pulmonary Disease Acute Exacerbation (AECOPD) from baseline to week 52.(Baseline up to week 52)
- The change from baseline in the St. George's Respiratory Questionnaire-COPD (SGRQ-C) total score(Weeks 0, 4, 12, 24,36,52)
- The proportion of subjects with a ≥4-point improvement from baseline in the total score of the St. George's Respiratory Questionnaire for COPD (SGRQ-C) at Weeks 4, 12, 24, 36, and 52(Weeks 0, 4, 12, 24,36,52)
- Changes from baseline in CAT(COPD Assessment Test) score at 4，12 ，24，36 and 52 weeks.(Weeks 0, 4, 12, 24，36，52)
- Safety and tolerability assessment(60 weeks)
- Immunogenicity Assessment(52 weeks)
- serum concentrations of 9MW1911(32 weeks)
- Biological Marker(52 weeks)
- Pharmacogenomics Characteristics(week 0)
Investigators
Study Sites (50)
Loading locations...
Similar Trials
Recruiting
Phase 3
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32
Completed
Not Applicable
A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed DyslipidemiaNCT07278830Shenzhen Salubris Pharmaceuticals Co., Ltd.214
Recruiting
Phase 2
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)NCT07268638Akebia Therapeutics60
Recruiting
Phase 2
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)NCT07280156Protalix150
Not yet recruiting
Not Applicable
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）NCT07274137MindRank AI Ltd738